PEVIA

Pan Ebola vaccine innovative approach

Summary

The devastating Ebola outbreak that struck western Africa in 2014-2016 left over 11 000 dead, including many medical workers. The outbreak highlighted the urgent need for safe, effective vaccines against the highly infectious disease.

There are a number of promising Ebola vaccines in development, and studies suggest that they are both safe and effective. Nevertheless, their large-scale deployment could be limited by issues such as the fact that they need to be stored at extremely low temperatures (-80°C). The goal of the PEVIA project is to develop second generation Ebola vaccines based on the proteins found on the surface of the virus. The project team is using the prime-boost approach, in which one vaccine is given to prime the immune system, and a second (different) vaccine is given to boost the immune response. The project hopes that the resulting regimen will be better suited to large-scale vaccination programmes in sub-Saharan countries, most notably because it will not require storage at low temperatures. In addition, PEVIA aims to develop innovative tools and methods to facilitate the development of new vaccine candidates for Ebola and related diseases, as well as novel diagnostic tests that can be deployed in the field.

Participants

  Show participants on map
EFPIA companies
  • Vaxeal Research, Evry, France
Universities, research organisations, public bodies, non-profit groups
  • Assistance Publique Hopitaux De Paris, Paris, France
  • Bernhard-Nocht-Institut Fuer Tropenmedizin, Hamburg, Germany
  • Centre Hospitalier Regional Et Universitaire De Lille, Lille, France
  • Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
  • Centre National De La Recherche Scientifique Cnrs, Paris, France
  • Commissariat A L Energie Atomique Et Aux Energies Alternatives, Paris, France
  • Ifakara Health Institute Trust, Dar es Salaam, Tanzania (United Republic of)
  • Istituto Nazionale Per Le Malattie Infettive Lazzaro Spallanzani-Istituto Di Ricovero E Cura A Carattere Scientifico, Rome, Italy
  • Istituto Superiore Di Sanita, Roma, Italy
  • Leibniz-Institut Fur Virologie, Hamburg, Germany
  • Universite D'Abomey-Calavi, Cotonou, Benin
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Excellgene SA, Monthey, Switzerland
  • Oligovax, Paris, France
Third parties
  • Institut National De La Sante Et De La Recherche Medicale, Paris, France

Participants
NameIHI funding in €
Assistance Publique Hopitaux De Paris1 297 406
Bernhard-Nocht-Institut Fuer Tropenmedizin182 500
Centre Hospitalier Regional Et Universitaire De Lille603 125
Centre National De La Recherche Scientifique Cnrs454 195
Commissariat A L Energie Atomique Et Aux Energies Alternatives1 040 108
Ifakara Health Institute Trust502 000
Istituto Nazionale Per Le Malattie Infettive Lazzaro Spallanzani-Istituto Di Ricovero E Cura A Carattere Scientifico273 650
Istituto Superiore Di Sanita246 887
Leibniz-Institut Fur Virologie81 250
Oligovax863 000
Universite D'Abomey-Calavi566 312
 
Third parties
NameFunding in €
Institut National De La Sante Et De La Recherche Medicale79 137
 
Total Cost6 189 570